• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Butterfly Network Inc.

    3/7/25 4:05:37 PM ET
    $BFLY
    Medical Electronics
    Health Care
    Get the next $BFLY alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 6)


    Butterfly Network, Inc.

    (Name of Issuer)


    Class A common stock, par value $0.0001 per share, Class B common stock, par value $0.0001 per share

    (Title of Class of Securities)


    124155102

    (CUSIP Number)


    Jonathan M. Rothberg, Ph.D.
    c/o Butterfly Network, Inc., 1600 District Avenue
    Burlington, MA, 01803
    (781) 557-4800

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    03/05/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    124155102


    1 Name of reporting person

    Rothberg Jonathan M.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    8,866,114.00
    8Shared Voting Power

    726,696.00
    9Sole Dispositive Power

    8,866,114.00
    10Shared Dispositive Power

    726,696.00
    11Aggregate amount beneficially owned by each reporting person

    9,592,810.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    4.4 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    This Reporting Person's table is for Class A common stock. Rows 7, 9 and 11 consists of (i) 2,641,924 shares of Class A common stock of Butterfly Network, Inc. (f/k/a Longview Acquisition Corp.) (the "Issuer") held by Jonathan M. Rothberg, Ph.D., (ii) stock options to purchase 21,645 shares of Class A common stock of the Issuer which are exercisable within 60 days of March 7, 2025, held by Dr. Jonathan M. Rothberg, (iii) 6,202,545 shares of Class A common stock of the Issuer distributed from 2012 JMR Trust Common, LLC and held by entities owned by trusts created for the benefit of Dr. Jonathan Rothberg's children. Rows 8, 10 and 11 consists of 726,696 shares of Class A common stock of the Issuer held by Dr. Rothberg's spouse. Row 13 is calculated based on 216,496,214 shares of Class A common stock of the Issuer outstanding as of February 13, 2025.


    SCHEDULE 13D

    CUSIP No.
    124155102


    1 Name of reporting person

    Rothberg Jonathan M.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    26,426,937.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    26,426,937.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    26,426,937.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    100 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    This Reporting Person's table is for Class B common stock. Rows 7, 9 and 11 consists of 26,426,937 shares of Class B common stock of the Issuer held by 4C Holdings I, LLC, 4C Holdings II, LLC, 4C Holdings III, LLC, 4C Holdings IV, LLC and 4C Holdings V, LLC. Row 13 is calculated based on 26,426,937 shares of Class B common stock of the Issuer outstanding as of February 13, 2025.


    SCHEDULE 13D

    CUSIP No.
    124155102


    1 Name of reporting person

    4C Holdings I, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    9,716,596.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    9,716,596.00
    11Aggregate amount beneficially owned by each reporting person

    9,716,596.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    36.8 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    This Reporting Person's table is for Class B common stock. Row 13 is calculated based on 26,426,937 shares of Class B common stock of the Issuer outstanding as of February 13, 2025.


    SCHEDULE 13D

    CUSIP No.
    124155102


    1 Name of reporting person

    4C Holdings II, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,621,701.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,621,701.00
    11Aggregate amount beneficially owned by each reporting person

    2,621,701.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    9.9 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    This Reporting Person's table is for Class B common stock. Row 13 is calculated based on 26,426,937 shares of Class B common stock of the Issuer outstanding as of February 13, 2025.


    SCHEDULE 13D

    CUSIP No.
    124155102


    1 Name of reporting person

    4C Holdings III, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,621,701.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,621,701.00
    11Aggregate amount beneficially owned by each reporting person

    2,621,701.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    9.9 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    This Reporting Person's table is for Class B common stock. Row 13 is calculated based on 26,426,937 shares of Class B common stock of the Issuer outstanding as of February 13, 2025.


    SCHEDULE 13D

    CUSIP No.
    124155102


    1 Name of reporting person

    4C Holdings IV, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    2,621,701.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    2,621,701.00
    11Aggregate amount beneficially owned by each reporting person

    2,621,701.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    9.9 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    This Reporting Person's table is for Class B common stock. Row 13 is calculated based on 26,426,937 shares of Class B common stock of the Issuer outstanding as of February 13, 2025.


    SCHEDULE 13D

    CUSIP No.
    124155102


    1 Name of reporting person

    4C Holdings V, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    8,845,238.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    8,845,238.00
    11Aggregate amount beneficially owned by each reporting person

    8,845,238.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    33.5 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    This Reporting Person's table is for Class B common stock. Row 13 is calculated based on 26,426,937 shares of Class B common stock of the Issuer outstanding as of February 13, 2025.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Class A common stock, par value $0.0001 per share, Class B common stock, par value $0.0001 per share
    (b)Name of Issuer:

    Butterfly Network, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    1600 District Avenue, Burlington, MASSACHUSETTS , 01803.
    Item 1 Comment:
    Explanatory Note This Amendment No. 6 to Schedule 13D ("Amendment No. 6") amends and supplements the Schedule 13D filed on February 22, 2021, as amended by Amendment No. 1 filed on March 26, 2021, Amendment No. 2 filed on March 28, 2022, Amendment No. 3 filed on September 16, 2022, Amendment No. 4 filed on September 13, 2023 and Amendment No. 5 filed on August 30, 2024 (as amended, the "Schedule 13D") relating to the Class A common stock, par value $0.0001 per share, and Class B common stock, par value $0.0001 per share, of Butterfly Network, Inc. (f/k/a Longview Acquisition Corp.), a Delaware corporation (the "Issuer"). Information reported in the Schedule 13D remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment No. 6. Capitalized terms used but not defined herein have the meanings ascribed to them in the Schedule 13D.
    Item 4.Purpose of Transaction
     
    Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following: In connection with estate planning, entities owned by trusts created for the benefit of Dr. Jonathan Rothberg's children have entered into a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Plan"), a copy of which is attached hereto as Exhibit 5. Pursuant to the Plan, sales of up to 6,202,545 shares of Class A common stock may be effected during the plan sales period beginning following the cooling-off period contained in Rule 10b5-1(c) on July 7, 2025 and ending on July 3, 2026 in accordance with the terms and conditions of the Plan. The sale of shares of Class A common stock under the Plan is subject to minimum price parameters included in the Plan, and there is no assurance that any shares of Class A common stock will be sold under the Plan.
    Item 7.Material to be Filed as Exhibits.
     
    Item 7 of the Schedule 13D is hereby amended by adding the following exhibit: Exhibit No. 5 - Rule 10b5-1 Trading Plan

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Rothberg Jonathan M.
     
    Signature:/s/ Jonathan M. Rothberg
    Name/Title:Jonathan M. Rothberg, Ph.D.
    Date:03/07/2025
     
    Rothberg Jonathan M.
     
    Signature:/s/ Jonathan M. Rothberg
    Name/Title:Jonathan M. Rothberg, Ph.D.
    Date:03/07/2025
     
    4C Holdings I, LLC
     
    Signature:/s/ Jonathan M. Rothberg
    Name/Title:Jonathan M. Rothberg, Ph.D., Manager
    Date:03/07/2025
     
    4C Holdings II, LLC
     
    Signature:/s/ Jonathan M. Rothberg
    Name/Title:Jonathan M. Rothberg, Ph.D., Manager
    Date:03/07/2025
     
    4C Holdings III, LLC
     
    Signature:/s/ Jonathan M. Rothberg
    Name/Title:Jonathan M. Rothberg, Ph.D., Manager
    Date:03/07/2025
     
    4C Holdings IV, LLC
     
    Signature:/s/ Jonathan M. Rothberg
    Name/Title:Jonathan M. Rothberg, Ph.D., Manager
    Date:03/07/2025
     
    4C Holdings V, LLC
     
    Signature:/s/ Jonathan M. Rothberg
    Name/Title:Jonathan M. Rothberg, Ph.D., Manager
    Date:03/07/2025
    Get the next $BFLY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BFLY

    DatePrice TargetRatingAnalyst
    3/17/2025Outperform
    William Blair
    9/10/2024$3.00Buy
    Lake Street
    3/29/2023$2.25Neutral
    UBS
    11/29/2022$4.50Outperform
    Oppenheimer
    10/4/2022$9.50Buy
    B. Riley Securities
    12/17/2021$7.00Neutral
    UBS
    More analyst ratings

    $BFLY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Butterfly Network Reports First Quarter 2025 Financial Results

      Delivered on Quarterly Revenue and EBITDA Guidance Reiterate full year Revenue and Adjusted EBITDA guidance Quarterly Revenue of $21.2 million in Q1, representing 20% YoY growth Reduced Q1 Net Loss by 36% and Net Cash Used in Operations by 43% Raised $81.7 million of net proceeds through a public offering closed on January 31, 2025 Initiated clinical phase of Butterfly HomeCare congestive heart failure pilot program Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced financial results for the first quarter ended March 31, 202

      5/2/25 6:30:00 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Butterfly Network to Report First Quarter 2025 Financial Results on May 2, 2025

      Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report first quarter 2025 financial results on May 2, 2025 before the market opens. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and Heather Getz, Executive Vice President and Chief Financial and Operations Officer, will host a conference call and webcast at 8:00 am ET on May 2 to discuss the financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly's Investor Relations website at Eve

      4/17/25 4:05:00 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Butterfly Network to Participate at Oppenheimer 35th Annual Healthcare MedTech & Services Virtual Conference on March 18, 2025

      Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly") a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that it will participate at the Virtual Oppenheimer 35th Annual Healthcare MedTech & Services Conference on March 18, 2025. Joseph DeVivo, President, Chief Executive Officer & Chairman and Heather Getz, Executive Vice President & Chief Financial and Operations Officer will host one-on-one investor meetings and take part in a Fireside Chat at 11:20am EDT. A webcast of the Fireside Chat will be available in the Events & Presentations section of the Butterfly investor website. To schedule a one-on-one meeting with Mr. DeVivo

      3/5/25 8:05:00 AM ET
      $BFLY
      Medical Electronics
      Health Care

    $BFLY
    Leadership Updates

    Live Leadership Updates

    See more
    • Butterfly Network Appoints Steve Cashman as Chief Business Officer

      Seasoned Healthcare Leader to Drive Growth Strategy and Amplify Continued Commercial Momentum Butterfly Network, Inc. (NYSE:BFLY), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced the appointment of Steve Cashman as Chief Business Officer (CBO), effective today. Cashman joins Butterfly at an exciting juncture, following the Company's successful launch of its third-generation Butterfly iQ3 and historic revenue performance in the first half of 2024. Cashman will join Butterfly's Executive Management Team, overseeing the Company's global sales, marketing, product and corporate strategy. This press release f

      9/3/24 8:30:00 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Avive Welcomes Katerina Miras as Vice President of Marketing

      SAN FRANCISCO, Aug. 20, 2024 /PRNewswire/ -- Avive Solutions, Inc., a manufacturer of innovative Automated External Defibrillators (AEDs) and software solutions to improve access to AEDs and response to cardiac arrest emergencies, is excited to announce the appointment of Katerina Miras as their Vice President of Marketing. A visionary marketing leader with extensive experience in medtech, Miras brings a wealth of expertise in creating memorable healthcare brands that accelerate commercial growth. "I am honored to join Avive's leadership team at such a transformative time for

      8/20/24 9:00:00 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Myomo Appoints Heather Getz to its Board of Directors

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership. She has significant expertise in finance, reimbursement, investor relations, compliance, M&A and strategic plannin

      3/28/24 4:05:00 PM ET
      $BFLY
      $MYO
      Medical Electronics
      Health Care
      Industrial Specialties

    $BFLY
    SEC Filings

    See more
    • SEC Form 144 filed by Butterfly Network Inc.

      144 - Butterfly Network, Inc. (0001804176) (Subject)

      5/5/25 3:27:27 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • SEC Form 10-Q filed by Butterfly Network Inc.

      10-Q - Butterfly Network, Inc. (0001804176) (Filer)

      5/2/25 7:28:43 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Butterfly Network Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Butterfly Network, Inc. (0001804176) (Filer)

      5/2/25 7:25:19 AM ET
      $BFLY
      Medical Electronics
      Health Care

    $BFLY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Robbins Larry bought $262,251 worth of shares (244,774 units at $1.07) (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      9/4/24 4:34:48 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Director Robbins Larry bought $1,683,373 worth of shares (1,676,869 units at $1.00) (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      8/30/24 4:18:35 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • President & CEO Devivo Joseph bought $98,519 worth of shares (104,000 units at $0.95), increasing direct ownership by 2% to 7,009,221 units (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      8/7/24 4:34:48 PM ET
      $BFLY
      Medical Electronics
      Health Care

    $BFLY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CFO & COO Getz Heather C sold $144,069 worth of shares (65,456 units at $2.20), decreasing direct ownership by 2% to 2,919,274 units (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      5/7/25 4:18:53 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • President & CEO Devivo Joseph sold $780,684 worth of shares (320,215 units at $2.44), decreasing direct ownership by 4% to 7,249,789 units (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      4/29/25 5:40:11 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Chief Technology Officer Stoica Andrei G sold $3,908 worth of shares (1,805 units at $2.17), decreasing direct ownership by 0.11% to 1,600,182 units (SEC Form 4)

      4 - Butterfly Network, Inc. (0001804176) (Issuer)

      4/3/25 5:24:38 PM ET
      $BFLY
      Medical Electronics
      Health Care

    $BFLY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Butterfly Network

      William Blair initiated coverage of Butterfly Network with a rating of Outperform

      3/17/25 7:23:53 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Lake Street initiated coverage on Butterfly Network with a new price target

      Lake Street initiated coverage of Butterfly Network with a rating of Buy and set a new price target of $3.00

      9/10/24 8:07:39 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • UBS initiated coverage on Butterfly Network with a new price target

      UBS initiated coverage of Butterfly Network with a rating of Neutral and set a new price target of $2.25

      3/29/23 7:12:28 AM ET
      $BFLY
      Medical Electronics
      Health Care

    $BFLY
    Financials

    Live finance-specific insights

    See more
    • Butterfly Network to Report First Quarter 2025 Financial Results on May 2, 2025

      Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report first quarter 2025 financial results on May 2, 2025 before the market opens. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and Heather Getz, Executive Vice President and Chief Financial and Operations Officer, will host a conference call and webcast at 8:00 am ET on May 2 to discuss the financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly's Investor Relations website at Eve

      4/17/25 4:05:00 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Butterfly Network to Report Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025

      Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report fourth quarter and full year 2024 financial results on Friday, February 28, 2025, at 8:00 am ET. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and Heather Getz, Executive Vice President and Chief Financial and Operations Officer, will host a conference call and webcast before the market opens on February 28 to discuss the financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly

      2/18/25 8:05:00 AM ET
      $BFLY
      Medical Electronics
      Health Care
    • Butterfly Network Reports Third Quarter 2024 Financial Results

      Delivered Quarterly Revenue of $20.6mm, 33% YoY Growth Raises Full Year Revenue and Adjusted EBITDA Guidance Delivered quarterly Revenue of $20.6 million in Q3, representing 33% YoY growth Reduced Q3 Net Loss by 38% and Net Cash Used in Operations by 50% Launched iQ3 in Europe and opened new markets in Indonesia, the Netherlands, and Belgium Announced the formation of Octiv™, a wholly owned subsidiary focused on bringing Butterfly's chip to new sectors Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced financial results for th

      11/1/24 6:30:00 AM ET
      $BFLY
      Medical Electronics
      Health Care

    $BFLY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Butterfly Network Inc.

      SC 13D/A - Butterfly Network, Inc. (0001804176) (Subject)

      9/3/24 7:10:06 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Butterfly Network Inc.

      SC 13D/A - Butterfly Network, Inc. (0001804176) (Subject)

      8/30/24 4:05:41 PM ET
      $BFLY
      Medical Electronics
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Butterfly Network Inc.

      SC 13G/A - Butterfly Network, Inc. (0001804176) (Subject)

      7/8/24 4:32:42 PM ET
      $BFLY
      Medical Electronics
      Health Care